Abstract 392 Table 1 PFS in higher-risk and lower-risk SOLO1 subgroups by investigator and BICR assessment

	Median PFS, months		HR (95% CI)
	Olaparib	Placebo	
Investigator			
Higher risk	39.0	11.1	0.34 (0.24–0.48)
Lower risk	NR	21.9	0.33 (0.20–0.52)
BICR			
Higher risk	NR	11.3	0.32 (0.22–0.49)
Lower risk	NR	19.2	0.29 (0.17–0.50)

Disclosures Nicoletta Colombo: Consulting fees or advisory role from Roche/Genentech, PharmaMar, AstraZeneca, Clovis Oncology, Pfizer, MSD Oncology, Takeda, Tesaro, BioCad and GlaxoSmithKline; honoraria from Roche/Genentech, AstraZeneca, Tesaro and PharmaMar. William Bradley: Nothing to disclose. Kathleen Moore: Advisory board fees from Advaxis, Aravive, AstraZeneca, Clovis, Eisai, Genentech/Roche, Immunogen, Janssen, Merck, Oncomed, Pfizer, Samumed, Tesaro, VBL Therapeutics. Antonio González-Martín: Speaker role/consulting fees from AstraZeneca, PharmaMar, Roche, Tesaro; consulting fees from Clovis Oncology, Genmab, Immunogen, MSD, Pfizer. Giovanni Scambia: Nothing to disclose. Ana Oaknin: Consulting fees from AstraZeneca, Clovis Oncology, Genmab, Immunogen, PharmaMar, Roche, Tesaro. Michael Friedlander: Honoraria and speaker role/advisory boards from AstraZeneca; advisory board fees from Lilly, MSD, Takeda, Novartis; non-remunerated consulting for AbbVie; research funding from Beigene, AstraZeneca, Novartis. Elizabeth S. Lowe: Shareholder and employee of AstraZeneca. Philip Rowe: Shareholder and employee of AstraZeneca. Paul DiSilvestro: Consulting fees from AstraZeneca, Tesaro.

405

REAL-LIFE RESPONSE TO STANDARD OF CARE IN ADVANCED OVARIAN CANCER – AN OBSERVATIONAL MULTI-NATIONAL COHORT STUDY (RESPONSE)

¹Christian Marth, ²Heini Lassus, ³Kristina Lindemann, ⁴Els Van Nieuwenhuyen, ⁵Anne Weng Ekman-Gade, ⁶Jesper Hansen, ⁷Klaus Kaae Andersen, ⁸Jacob Korach. ¹Medical University Innsbruck; Department of Obstetrics and Gynecology; ²Helsinki University Hospital and University of Helsinki; Department of Gynecology and Obstetrics; ³Oslo Universitetssykehus, Kreftklinikken; Avdeling for Gynekologisk Kreft; ⁴University Hospital Leuven; Department of Obstetrics and Gynecology; ⁵Juliane Marie Centre, Rigshospitalet; Department of Gynaecology; ⁶Astrazeneca; Medical Affairs; ⁷Astrazeneca; Medical Evidence; ⁸Sheba Medical Center

10.1136/ijgc-2020-ESGO.131

Introduction/Background Recent randomized clinical trials have demonstrated convincing effects of integrating PARP inhibitors (PARPi) and combination of PARPi + bevacizumab (anti-VEGF) into first line (1L) treatment of selected groups of advanced stage ovarian cancer (OC) patients. However, it remains unclear to which extent eligibility of PARPi treatment translates into a real-world setting, where the impact of patient heterogeneity and differences in national clinical practices may influence the potential for PARPi treatment. The aim of this study is to describe treatment strategies and outcomes of advanced OC; and to estimate the proportion of patients potentially eligible for 1L PARPi maintenance therapy and for concomitant anti-VEGF treatment practice using observational data in a multi-national setting (RESPONSE).

Methodology This international, multi-centre, observational study, includes real-world data on diagnostic work-up, standard of care, clinical outcomes and treatment for around 1000 patients with advanced OC (≥ 120 patients/country). Last index date is 1st April 2018, ensuring at least 20 months of follow-up. Potential PARPi eligibility is defined as having no macroscopic residual disease (<1 cm) following upfront surgery and/or having a clinical complete response/partial

Abstract 405 Figure 1

response (CR/PR) following completion of 1L chemotherapy according to the label. Eligibility for PARPi treatment will be analysed prospectively by time-to-event by individual country, all countries combined, and in relation to treatment patterns. Finally, between-country variations will be described in relation to 1L treatment patterns and national guidelines.

Results In total, eight countries, Austria, Belgium, Denmark, Finland, Israel, Netherlands, Norway, and Portugal, are included in the study (study flow chart; figure 1). Data collection is ongoing and will be finalized by Q1 2021. Inclusion of 120 patients per site will provide precise estimates of local PARPi eligibility (error margin of 4%) and sufficient power to detect clinical meaningful differences in PARPi eligibility between any two countries.

Conclusion International real-world OC data is currently scarce. RESPONSE will add to the current knowledge regarding factors influencing eligibility to 1L PARPi or PARPi + anti-VEGF maintenance treatment in individual countries, and enable mapping of patient characteristics and key variables in the 1L treatment pathway, such as timing and outcome of surgery, including concomitant anti-VEGF treatment.

Disclosures Professor Christian Marth has received funded research from EU, FWF, AstraZeneca and Roche, Honoraria/Expenses from Roche, Novartis, Amgen, MSD, Pharmamar, AstraZeneca, and Tesaro, and has performed Consulting/Advisory Boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex, and Tesaro.

Dr Jacob Korach has nothing to disclose.

Dr Kristina Lindemann has acted as Consultant for AstraZeneca, Speaker for AstraZeneca and GSK, and participated in Advisory Boards for AstraZeneca and GSK.

Dr Anne Weng Ekmann-Gade has received research grants for the current trial

Dr E Van Nieuwenhuysen has nothing to disclose.

Dr Heini Lassus has nothing to disclose.

Dr Klaus Kaas Andersen is employed by AstraZeneca.

Jesper Hansen is employed by AstraZeneca.

413

PROGNOSTIC VALUE OF THE TUMOR INFILTRATING LYMPHOCYTES AND THE NEUTROPHIL-TO-LYMPHOCYTE RATIO IN PATIENTS WITH ADVANCED OVARIAN CANCER

¹Beatriz Álvarez-Abril, ¹Esmeralda García, ¹Pilar de la Morena, ¹Alejandra Ivars, ¹Manuel Sánchez, ²Asunción Chaves, ³Francisco Pastor, ¹Gema Marín, ¹Francisco Ayala, ¹Elena García Martínez. ¹Hospital General Universitario Morales Meseguer; Hematology and Medical Oncology; ²Hospital General Universitario Morales Meseguer; Pathology; ³Hospital General Universitario Reina Sofía; Pathology

10.1136/ijgc-2020-ESGO.132

Introduction/Background Tumor infiltrating lymphocytes (TIL) and Neutrophil-to-lymphocyte ratio (NLR) have been objectified as independent prognostic factors in different tumours. There is not enough knowledge about the prognostic value of these two factors as a combination. This analysis aims to study the prognostic significance of TIL and NLR in patients with advanced ovarian cancer (OC).

Methodology Observational, single-center and retrospective analysis of a cohort of 135 patients with advanced stage OC treated between 2002 and 2019. Histological samples of ovarian tissue from the surgery of 92 patients were requested, with informed consent, and tissue microarrays (TMA) were constructed. For the TIL study, immunohistochemical staining of the TMA was made

and a quantitative analysis was performed through the morphometric analysis of the lymphocytes. Samples were categorized in relation to total area as TIL 0 = absence; 1 = <25%; 2 = 25–50%; 3 = 50–75%; 4 ≥ 75%. Neutrophils and lymphocytes levels in peripheral blood at the diagnosis were collected to estimate NLR. Survival analysis was performed using Cox regression.

Results Average age 66 years (36–84 years). Median overall survival (OS): 56 months (0.92–154 m). FIGO stage: 80% III, 20% IV. Histology: 87.2% papillary serous. ECOG: 18.5% ECOG 2 at diagnosis. Surgery: primary cytoreduction/after neo-adjuvant treatment: 59/59 patients. TIL and NLR study: Both variables were not correlated (Spearman's rho: -0.259, p = 0.106). 75% of patients had TILCD3 infiltration <25%. Median NLR = 3.72. The univariate analysis showed a higher OS in patients with TILCD3 > 25% (HR 0.448, 95% CI 0.19 – 1.02;

Abstract 413 Figure 1